tetano
Editor, Senior Moderator
J Med Microbiol
. 2022 Nov;71(11).
doi: 10.1099/jmm.0.001591.
Thrombotic storm in coronavirus disease 2019: from underlying mechanisms to its management
Arghavan Zebardast[SUP] 1 2 [/SUP], Tayebeh Latifi[SUP] 1 [/SUP], Mehdi Shabani[SUP] 1 [/SUP], Ali Hasanzadeh[SUP] 3 [/SUP], Manizheh Danesh[SUP] 4 [/SUP], Sara Babazadeh[SUP] 5 [/SUP], Farzin Sadeghi[SUP] 6 [/SUP]
Affiliations
Abstract
Introduction. Coronavirus disease 2019 (COVID-19) identified in December 2019 in Wuhan, China, is associated with high mortality rates worldwide.Hypothesis/Gap Statement. Thrombotic problems, such as coagulopathy, are common in COVID-19 patients. Despite anticoagulation, thrombosis is more common in patients in the intensive care unit and patients with more severe disease. Although the exact mechanisms of coagulopathy in COVID-19 patients are still unclear, studies showed that overactivation of the renin-angiotensin system (RAS), cytokine storm, endothelial damage, formation of neutrophil extracellular traps (NETs), and also extracellular vesicles (EVs) in response to COVID-19 induced inflammation can lead to systemic coagulation and thrombosis.Aim. The management of COVID-19 patients requires the use of basic and readily available laboratory markers, both on admission and during hospitalization. Because it is critical to understand the pathophysiology of COVID-19 induced coagulopathy and treatment strategies, in this review we attempt to explain the underlying mechanism of COVID-19 coagulopathy, its diagnosis, and the associated successful treatment strategies.Conclusion. The exact mechanisms behind COVID-19-related coagulopathy are still unclear, but several studies revealed some mechanisms. More research is needed to determine the best anticoagulant regimen and to study other therapeutic options.
Keywords: COVID-19; SARS-CoV-2; coagulation; coagulopathy; inflammation; thrombosis.
. 2022 Nov;71(11).
doi: 10.1099/jmm.0.001591.
Thrombotic storm in coronavirus disease 2019: from underlying mechanisms to its management
Arghavan Zebardast[SUP] 1 2 [/SUP], Tayebeh Latifi[SUP] 1 [/SUP], Mehdi Shabani[SUP] 1 [/SUP], Ali Hasanzadeh[SUP] 3 [/SUP], Manizheh Danesh[SUP] 4 [/SUP], Sara Babazadeh[SUP] 5 [/SUP], Farzin Sadeghi[SUP] 6 [/SUP]
Affiliations
- PMID: 36346830
- DOI: 10.1099/jmm.0.001591
Abstract
Introduction. Coronavirus disease 2019 (COVID-19) identified in December 2019 in Wuhan, China, is associated with high mortality rates worldwide.Hypothesis/Gap Statement. Thrombotic problems, such as coagulopathy, are common in COVID-19 patients. Despite anticoagulation, thrombosis is more common in patients in the intensive care unit and patients with more severe disease. Although the exact mechanisms of coagulopathy in COVID-19 patients are still unclear, studies showed that overactivation of the renin-angiotensin system (RAS), cytokine storm, endothelial damage, formation of neutrophil extracellular traps (NETs), and also extracellular vesicles (EVs) in response to COVID-19 induced inflammation can lead to systemic coagulation and thrombosis.Aim. The management of COVID-19 patients requires the use of basic and readily available laboratory markers, both on admission and during hospitalization. Because it is critical to understand the pathophysiology of COVID-19 induced coagulopathy and treatment strategies, in this review we attempt to explain the underlying mechanism of COVID-19 coagulopathy, its diagnosis, and the associated successful treatment strategies.Conclusion. The exact mechanisms behind COVID-19-related coagulopathy are still unclear, but several studies revealed some mechanisms. More research is needed to determine the best anticoagulant regimen and to study other therapeutic options.
Keywords: COVID-19; SARS-CoV-2; coagulation; coagulopathy; inflammation; thrombosis.